Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

RCT (n=253) shows at 12 weeks, only 50mg bd dose of gefapixant produced a statistically significant reduction in awake cough frequency after 12 weeks compared to placebo (18.2 coughs/hour with placebo vs 11.3 coughs/hour with gefapixant 50mg; p=0.0027).

SPS commentary:

Gefapixant is a purinergic P2X3 receptor antagonist currently in phase III development for chronic cough, including cough with idiopathic pulmonary fibrosis.


The Lancet Respiratory Medicine